- Home
- SFST vs CTNM Comparison
SFST vs CTNM Comparison
Compare SFST & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SFST | CTNM |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.4M | 328.1M |
| IPO Year | 1999 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SFST | CTNM |
|---|---|---|
| Price | $52.50 | $11.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $51.00 | $20.00 |
| AVG Volume (30 Days) | 31.1K | ★ 179.4K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.78 | N/A |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $109,391,000.00 | N/A |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $17.49 | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | ★ 21.32 | N/A |
| 52 Week Low | $29.14 | $3.35 |
| 52 Week High | $52.60 | $15.25 |
Technical Indicators
Market Signals| Indicator | SFST | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 72.07 | 49.47 |
| Support Level | $50.29 | $10.42 |
| Resistance Level | $52.60 | $11.12 |
| Average True Range (ATR) | 1.55 | 0.82 |
| MACD | 0.21 | -0.03 |
| Stochastic Oscillator | 94.68 | 27.41 |
Price Performance
Historical ComparisonAbout SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.